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he appearance of pharmacological treatments
in the 1950s was a milestone in modern psychiatric his-
tory. Today, the goals of psychiatric treatment are to
reduce and,ideally,eliminate symptoms,and prevent new
episodes of illness.The final objective is remission, an
asymptomatic state in which the patient returns to a fully
functional personal, family, and social life. With psy-
chotropic drugs,therapy has changed from a moral and
human approach to treatment based on the biopsy-
chosocial concept of the illness,as defined by the World
Health Organization (WHO).
While drugs are effective in treating psychiatric disorders,
some patients have no or only a partial response to treat-
ment.This affects not only the patient,but also the fam-
ily and the professionals caring for that patient.The lack
of response should be considered as a multifaceted prob-
lem,involving variables inherent to the illness itself,as
well as those relating to the patient and psychosocial fac-
tors.Although it may seem very basic,one of the main
factors to be considered when evaluating a patient
responding poorly to treatment is the way in which the
treatment is being carried out.
There are two concepts related to the way in which 
treatment is carried out: compliance and adherence.
Compliance includes many variables,but refers mainly to
the degree to which patients follow physicians’ instruc-
tions (primarily the number of pills taken daily accord-
ing to the schedule prescribed).For many authors,com-
pliance is a passive behavior on the part of the patient.In
contrast, adherence implies active behavior in which a
patient’s beliefs with respect to mental illness and drugs
are key to the decision of whether to cooperate volun-
tarily with the treatment regimen.
1,2 In most psychiatric
cases,patients with the freedom to do so choose profes-
sionals who have the same ideas as themselves, which
should increase likelihood of adhering to the prescrip-
tions.However,in a group of patients in primary health
care, suffering from dysthymia and mild depression, it
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Poor response to treatment:
beyond medication
César Carvajal, MD
T
In psychiatry, one of the main factors contributing to poor
response to pharmacological treatment is adherence.
Noncompliance with maintenance treatments for chronic
illnesses such as schizophrenia and affective disorders can
exceed 50%. Poor adherence can be due to drug-related
factors (tolerance, complexity of prescription, side effects,
or cost), patient-related variables (illness symptoms,
comorbidity, insight capacity, belief system, or sociocul-
tural environment), and physician-related factors (com-
munication or psychoeducational style). Psychosocial treat-
ments must be used in conjunction with medication
during the maintenance phase to improve adherence to
treatment and to achieve—through the management of
psychological variables—better social, work, and family
functioning. This article reviews the concepts of adherence
and noncompliance, and their impact on maintenance
treatments, as well as the effect of dealing with psy-
chosocial factors in psychiatric treatment. 
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adherence to treatment, and even that the individuals
who did not consider depression to be a biological illness
responded best to antidepressants.
3
Noncompliance in self-administered treatment is fre-
quent,especially in long-term therapy,when compliance
can be as low as 50%.In cases of antibiotic treatment for
acute infections,compliance is 75% at the beginning of
treatment,but drops to 25% at the end of the regimen.
4
In addition, compliance and adherence are frequently
overestimated and, consequently, when a patient
responds poorly to treatment,these variables are rarely
considered responsible for the result.
1
Overdosage,underdosage,or taking medication at erratic
intervals can bring on adverse effects and make treat-
ment ineffective.Noncompliance is associated with poor
clinical evolution.The ideal combination is compliance
and successful treatment; this situation should bring
about a “virtuous circle” to help maintain long-term
treatment.However,there are times when a patient has
a high level of compliance,but treatment is only partially
successful,in which case the diagnosis and/or treatment
must be reevaluated.An issue worthy of further research
is the compliance threshold necessary for obtaining an
acceptable response to therapy.
Compliance depends on numerous factors. Variables
related directly to the medication are tolerance,undesir-
able side effects (eg,neurological,endocrinological,and
anticholinergic),and cost.Patient-related factors include
the symptoms of the pathology (especially psychotic
symptoms), comorbidity, insight capacity, the patient’s
sociocultural background,and his or her beliefs regard-
ing the usefulness of the treatments. A good doctor-
patient relationship should be established at the first visit;
a general and psychopathological clinical study will pro-
vide the means for formulating a diagnosis and treat-
ment,and will allow for the beginning of a psychoeduca-
tional process to promote adherence to treatment.
Measurement of compliance is a complex issue.It can be
evaluated directly by measuring the presence of the med-
ication or a metabolite in the blood,urine,or saliva,espe-
cially when these are present for relatively long periods.
Noncompliance can be evaluated indirectly from the
patient’s failure to go to appointments,a poor response
to treatment (when the usual doses of the medication
have been taken),the patient’s report of his or her com-
pliance,a pill count,the presence of expected side effects
(eg,dry mouth from taking anticholinergics),and from
pharmacy records when the patient regularly purchases
the medication at the same place.
Hack and Chow found that compliance with treatment
was lower among children than adults, and was lower
among psychiatric patients than those with other medical
pathologies,leading to the inference that children with
psychiatric disorders are at the highest risk for noncom-
pliance.
5 Financial factors can also restrict access to
proper psychopharmacological treatment (about one-
third of patients).
6
Information obtained from the patient,other health pro-
fessionals, and family members can provide subjective
data on compliance.In contrast,more precise informa-
tion can be obtained through electronic monitoring of
the prescribed doses by using medication bottles
equipped with a device in the lid that informs a computer
when the bottle was opened.This can also show the cor-
relation between the number of daily doses and compli-
ance.
7When a single daily dosage is prescribed,compli-
ance is 79%;compliance is 69% for two doses per day,
65% for three doses,and only 51% when four doses per
day are prescribed. The differences are significant
between one or two versus three or four daily doses,but
no significant difference was found between one and two
doses,or between three and four daily doses.
8
In the various medical or surgical specialties,the health
professional’s influence is crucial to improving adher-
ence,
9,10 and depends to a large extent on the physician’s
communication skills and his or her ability to listen and
respond to the patient.
11 Other factors that can improve
compliance are simplifying the treatment regimen,pro-
viding information and descriptions of a medication’s
possible side effects, encouraging social support, and
developing psychoeducational programs.Patients with
higher educational levels are also more likely to comply
with treatment.
For the purposes of this paper,noncompliance and lack
of adherence will be used interchangeably.The effects of
these and of psychosocial factors will be studied in situ-
ations of poor response to pharmacological treatments
in cases of schizophrenia and affective disorders.
Schizophrenia
Although pharmacological treatment of schizophrenia
has significantly improved the evolution of this disorder,
antipsychotics are still associated with side effects that
can undermine a patient’s quality of life, constitute a
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Any chronic illness such as schizophrenia involves a high
percentage of noncompliance. Although classic neu-
roleptics have significantly reduced the percentage of
relapses,noncompliance can vary from 11% to as high as
80%,
12-14 making it difficult to evaluate the true effective-
ness of drugs as an isolated therapeutic variable in this
illness. Noncompliance in schizophrenia can have fre-
quencies similar to that of other chronic illnesses such as
epilepsy, diabetes mellitus, and hypertension.
15 Poor
adherence is found in approximately two-thirds of rehos-
pitalized patients.
12 Low-adherence patients are 2.4 times
more likely to be hospitalized (and for longer stays) than
a patient who complies with treatment.
16 Of relapse
patients,40% have poor adherence to therapy.
12
Factors of noncompliance
In their evaluation of possible sociodemographic and ill-
ness factors affecting noncompliance,Agarwal et al found
that patients who were younger,had illnesses that occur
episodically and with a shorter evolution time,had fewer
side effects,misunderstood the positive symptoms,and
had a more negative subjective attitude toward medica-
tion, were more likely not to comply with treatment.
17
The Thought Disorder Subscale of the Brief Psychiatric
Rating Scale (BPRS) for psychopathologic evaluation
and the Neurological Effects Subscale of the UKU
(Udvalg for Kliniske Undersogelser, the Finnish
Committee for Clinical Trials) Side Effects Scale pre-
dicted a 24% variation rate in adherence.
18
For Linden et al,a positive outlook on the illness,over-
all evaluation of functioning,and the physician’s impres-
sion of the patient’s cooperation with treatment were
determining factors in 19% of the adherence variation in
a 2-year study of 122 outpatients with schizophrenia.
19 In
a group of 77 patients who were hospitalized and
treated with clozapine,evaluation at the time of release
and 3 months later showed that the therapeutic alliance
with the physician,delusions of grandeur,and a positive
attitude toward drugs had a significant influence on com-
pliance with treatment. In contrast, acquiring greater
knowledge of mental illness and its etiology and prog-
nosis were not factors in adherence.
20
In the initial phase of symptom stabilization, patients
with better adherence took higher doses of neuroleptics.
19
In addition, better performance on memory tests,
21 a
lower cognitive deficit,
22 and a system of directly super-
vised medication intake
23 were factors in better compli-
ance with treatment. A good therapeutic relationship
seems to be the best predictor of proper adherence
24;in
this respect,the use of clozapine,which requires a period
of appointments with blood tests, would bring about a
better therapeutic relationship.
25 Comorbidity with drug
abuse increases noncompliance.
26
The distinction established between covert noncompli-
ance (resulting from the side effects of neuroleptics) and
open noncompliance (caused by the characteristics of the
illness) is an interesting issue in the exploration of the
various factors that can bring about poor adherence.
15
Patients’ attitudes toward the side effects and potential
risks of neuroleptics also have an effect on adherence.
27
Patients taking classic neuroleptics frequently experience
extrapyramidal symptoms,which are also unpleasant for
family members.They can also cause weight gain (with
increased risk of diabetes mellitus and hyperlipemia),
which is poorly tolerated,
28 sedation,hyperprolactinemia,
prolonging of the Q-T interval,and arrhythmia.Children
and adolescents are more susceptible to the extrapyra-
midal symptoms, weight gain, and hyperprolactinemia
caused by neuroleptics, due to a higher density of
dopamine D2 receptors in the striatum during this period
of development.
29
While atypical neuroleptics cause fewer side effects than
conventional ones (particularly extrapyramidal symp-
toms)
30 and have a moderately higher adherence rate than
classic neuroleptics,
31 the possibility of covert noncompli-
ance should not be underestimated,and efforts to improve
adherence should be focused on minimizing the side
effects of future neuroleptics.It is noteworthy that depot
formulations are being developed for atypical neurolep-
tics with positive results,as in the case of risperidone.
32
In addition,providing good social support and possibly
administering depot neuroleptics may also be interesting
treatment strategies.While the advantages of depot over
oral neuroleptics have been described in terms of a lower
frequency of relapse,
33 these drugs are used relatively
infrequently.Valenstein et al found that 18% of 1307 vet-
erans with schizophrenia or schizoaffective disorder used
depot neuroleptics,despite the fact that the previous year
49% had been noncompliant with treatment;there were
also differences according to where the patients went for
appointments and their ethnic group.
34A direct correla-
tion has been found between higher doses of depot neu-
roleptics and a lower percentage of annual relapses (63%
with 25 mg haloperidol decanoate every 4 weeks versus
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35The risk of suspending neuroleptics
is higher in patients with positive symptoms or sedation,
but the risk is also present in those with few symptoms.
36
The risk factors proposed for poor adherence to antipsy-
chotic treatment are:
• Neuroleptic-related:side effects,complexity of prescrip-
tion,lack of clinical effectiveness,and drugs taken orally.
• Patient-related: severity of illness, substance abuse,
extreme age (young or elderly), negative beliefs with
respect to the medication,and other comorbid diagnoses.
• Physician-related:poor doctor-patient/health care team
relations,discrepancy between treatments proposed by
clinical guidelines and actual clinical practice,lack of a
well-structured therapeutic plan,and insufficient infor-
mation on the illness and its treatment.
• Environment-related:negative media information on
the illness and/or treatments,lack of family and social
support,financial difficulties,and negative attitude of
staff or other patients toward the treatment.
37
In a recent review,Thieda et al concluded that there is a
direct correlation between lower compliance with treat-
ment and higher costs in treating schizophrenia.
38
Psychosocial aspects
The psychosocial aspects of schizophrenia are gaining
importance daily in both the development and the treat-
ment of the illness.Ritsner et al found that psychosocial
factors had the greatest impact on patients’ quality of life
(20.9%),followed by the symptoms and associated dis-
tress (10.1%),and adverse side effects (3.2%).
39The find-
ings of Sibitz et al among family members caring for
patients are interesting: they show that while men are
more difficult to care for,women are less likely to adhere
to the treatment regimen and are less compliant with
psychosocial treatments.
40 In the development of the ill-
ness, in addition to neurobiological factors, social risk
variables are being taken more seriously;these include
having been born or raised in a city, social isolation,
migration,and having experienced significant life events
prior to the appearance of the psychosis.
41
The goals of maintenance treatment are to preserve the
clinical improvement made during the acute phase,pre-
vent exacerbation of symptoms,continue reducing psy-
chopathological phenomena,strengthen social and fam-
ily functions,and finally,improve schizophrenic patients’
quality of life. Long-term pharmacotherapy combined
with psychosocial treatments can be more effective than
drug therapy alone.
42,43 Psychosocial treatments are ori-
ented toward preventing relapses,reducing the revolving
door syndrome (rehospitalizations),and achieving bet-
ter response and remission among patients with poor
response to drugs.The various psychological treatments
used with schizophrenic patients bring about slow,grad-
ual changes.They must be adapted to each individual,
and the patient must collaborate in setting objectives in
order to ensure greater collaboration and adapt the treat-
ment to the cognitive deficits present.
44
Psychosocial therapies
Among the psychosocial treatments developed in schiz-
ophrenia are family psychoeducation,individual treat-
ment (short term to promote compliance and long term
to improve coping strategies),cognitive behavior ther-
apy,training in social skills,vocational rehabilitation,and
compensatory strategies to modify the environment for
better cognitive adaptation.
Family psychoeducation
Family psychoeducation provides the family with knowl-
edge about the diagnosis,symptoms,and pathophysiol-
ogy of schizophrenia.The role of medications is high-
lighted,as is the evolution of the illness.Family members
are considered to be cotherapists,and,through commu-
nication techniques, they are given support in finding
ways to solve problems and handle crisis situations.
A widely studied variable has been the stress the family
generates in the context of emotional interaction,called
expressed emotion. This concept developed from the
observation of patients that had been hospitalized and
responded well to medication, but suffered relapses
shortly after returning home,despite stable medication
levels.
45 Factors in expressed emotion are hostility,criti-
cal comments,and excessive emotional involvement on
the part of family members.A high level of expressed
emotion has been associated with more relapses,while
patients with less expressed emotion in their families
(more tolerant and less invasive) suffer fewer relapses.
46
Further studies have shown that expressed emotion is a
factor in not only schizophrenic relapses,but also appears
in other neuropsychiatric illnesses,
47,48 both in the family
and in other therapeutic situations.
49 Some families ben-
efit from learning communication techniques to better
handle better a psychiatric patient’s evolution.
50
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less of its intensity—is less important than maintenance
treatment with neuroleptics in reducing the risk of
relapse.
51Although no differences were found in the per-
centage of relapses or rehospitalizations,patients func-
tioned better socially when their families were dealt with
individually rather than in groups.
52
Individual treatment
Kemp et al found that individual treatment increased
adherence when patients were given four to six cognitive
motivation interviews during hospitalization,followed by
reinforcement sessions 3,6,and 12 months after release.
After 18 months of follow-up,the group participating in
the study was found to have achieved greater functional
improvement than the control group who only received
general advice and support.
53
The first phase of personal therapy focuses on the rela-
tionship between stress and symptoms.The second phase
includes training in psychorelaxation and cognitive
restructuring techniques for handling stressful situations,
and the final stage is geared toward developing voca-
tional and social initiatives in the community.Hogarty et
al found that 60% of patients who received personal
therapy were well adjusted socially over the long term.
54
Cognitive behavior therapy
Cognitive behavior therapy has been used to treat resid-
ual psychotic symptoms.The reinforcement of coping
strategies helps the patient to refrain from focusing on,
or to ignore, the content of some symptoms.Tarrier et
al studied two methods of psychosocial treatment over
3 months.
55 In a 2-year follow-up study,they found that
cognitive behavior therapy was not an improvement over
counseling in achieving some degree of improvement in
schizophrenic symptoms that do not respond to medica-
tion.However,the group that only received routine care
worsened during the follow-up study.
55There are numer-
ous studies on this type of psychotherapy in schizophre-
nia, but more research must be done in order to reach
more solid conclusions.
Social skills training
Social skills training is based on the learning theory,
which assumes that social behavior can be taught and
learned.Certain social behaviors are broken down into
their constituent parts,which are modeled and reinforced
through feedback.When Smith et al trained a group of
hospitalized patients,they found that 70% were coping
with the demands of community life 2 weeks after
release—an achievement associated with the skills
learned before release rather than with the symptoms.
56
In patients stabilized with fluphenazine, Marder et al
showed that training in social skills had better results in
achieving social adjustment than group therapy during
an 18-month follow-up study.
57
Vocational rehabilitation
Vocational rehabilitation evaluates the patient’s skills
and potential for working in a competitive job, and
seeks to place the patient in a suitable activity with
social and economic incentives.Less than 20% of schiz-
ophrenic patients hold a competitive job.
58 Bell et al fol-
lowed patients who were placed in jobs for 6 months;at
5 months they found that those who received a salary
worked more hours,had fewer symptoms and rehospi-
talizations,and participated more in work activities than
those who did not receive a salary.
59The family can be of
great assistance in helping the patient find work.
60
Affective disorders
Today,the goals of treatment are to reduce and eliminate
the signs and symptoms of depression,recover work and
psychosocial functioning,and achieve and maintain com-
plete remission of symptoms.
61The treatment structure is
threefold:an acute phase,followed by a continuation stage
and,finally,a maintenance program.Symptoms are most
likely to go into remission during the acute phase; thus,
every effort must be made to prescribe the antidepressant
with the greatest therapeutic value,in optimal doses and
with the fewest side effects.If necessary,combination or
potentiation strategies are used.After the 6- to 8-week
acute stage,25% to 35% of patients are in remission.
62A
lack of complete remission or discontinuation of treatment
increases the risk of relapse and recurrence.It has been
emphasized that antidepressants should be taken for
approximately 1 year in the dosage that was initially effec-
tive, and many patients stay on medication for a longer
time to achieve better evolution of the illness.
63
In a naturalistic follow-up study of 62 weeks,after a year
of treatment with fluoxetine,47% of patients’ symptoms
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(personal stress,marital difficulties,or a personal deci-
sion to discontinue taking the antidepressants).
64
Many patients whose symptoms do not disappear com-
pletely are considered resistant to treatment,although,
strictly speaking,this is a pseudoresistance that can be
caused by insufficient dosage,insufficient treatment time,
poor adherence,or clinical evolution.
65
Depression is an illness that is difficult to treat due to its
inherent characteristics,factors that affect the prescrip-
tion of medication and proper treatment (such as poor
adherence and low dosage),comorbidity,and ineffective
treatment.
66 A great deal of the enormous personal,
social, and economic cost brought on by depression is
due to poor social functioning,which has generally been
underestimated.While there are differences among the
various treatments available to achieve better social func-
tioning,it must be recognized than an improvement in
symptoms does not necessarily ensure better functioning
in society
67 or at work.
68
Factors affecting adherence
The arsenal of antidepressants available is much larger
today,and the new medications are as efficient as the old
tricyclics and monoamine oxidase inhibitors (MAOIs),
but with fewer side effects.Although information on the
diagnosis and treatment of depression has been publi-
cized in the media,nonadherence to therapy continues
to be a major problem.
Little research has been done into the factors associated
with noncompliance in treatment for affective disorders,
and nonadherence in unipolar and bipolar disorders has
been estimated to range from 10% to 60%.
69,70
Adherence studies using patients’ self-reports show that
patients tend to overestimate their compliance,especially
older subjects.
71
A patient’s beliefs about the illness, unpleasant side
effects,ineffective treatment,and cultural factors are all
variables in noncompliance.
72 Among teenagers pre-
scribed imipramine,it was determined that the opposi-
tional defiant disorder and family dysfunction affected
adherence to the medication, rather than the side
effects.
73
The latency period in the early stages of medication and
poor tolerance for antidepressants have an effect on
compliance.
74 In addition,the physician’s initial commu-
nication style significantly influences a patient’s attitude
toward the usefulness of antidepressants.
75 Patients’ atti-
tudes and beliefs about the illness and treatment have
proven to be as effective in predicting adherence as the
unpleasant side effects of the drugs.
69,70
Treatment with selective serotonin reuptake inhibitors
(SSRIs) is abandoned less frequently than therapy with
conventional and modern tricyclics,but the difference is
small and is based on short-term,controlled,randomized
trials.Therefore,in clinical practice,generalizations can-
not be made about a greater adherence to SSRIs.
76-78
Among SSRIs,fluoxetine had a better pattern of use dur-
ing a 2-year study when compared with sertraline and
paroxetine, which was consistent with clinical guides.
79
One curious finding was the low adherence to nefa-
zodone among a group of Hispanic patients over an
acute treatment period of 8 weeks.Despite the fact that
63% responded well to treatment,42% abandoned the
therapy before completion.
80 Using nefazodone with this
ethnic group may put the effectiveness of the treatment
at risk,especially considering that there were no differ-
ences in unpleasant side effects.
Studies on therapeutic response predictors in depression
have had varying results.Gender does not seem to be a
good predictor of evolution either in a fluoxetine main-
tenance treatment program
81 or in a lithium potentiation
treatment in tricyclic-resistant patients
82;in contrast,men
respond better to tricyclics,
83 and women to MAOIs
84 and
SSRIs.
83Although Quitkin et al found no gender differ-
ences in the use of tricyclics or fluoxetine, women
responded better to MAOIs, but without clinical rele-
vance.
85 Age is not an efficient evolution predictor
either
81,82; however, in a 4.5-year study among patients
who required hospitalization for depression, Tuma
observed that those over 65 had a worse prognosis than
younger patients, particularly due to health problems,
dementia,and death.
86
Since psychosocial functioning improves more slowly
than depressive symptoms,
87 the maintenance phase of
treatment is particularly important. However, it was
found that the most significant progress in psychosocial
variables occurred during the acute phase of antidepres-
sive treatment.
88
Patients with more severe problems with everyday activ-
ities
87 and who lack a good social support system
89-91 have
a worse prognosis.In turn,those from higher social and
economic groups have better evolution,
92 while patients
from lower income groups have more persistent depres-
sive symptoms.
93
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Sirey et al evaluated adherence to acute treatment and
found that the most compliant patients were (i) less
likely to view depression as a stigma; (ii) more severe
cases; (iii) over 60 years of age; and (iv) those without
personality disorders.
94With respect to long-term adher-
ence, in a group of patients who responded well to flu-
oxetine at 8 weeks,a follow-up study at 26 weeks found
that those who had abandoned treatment early (before
2 months) suffered more social maladjustment than
those who completed the study. Likewise, subjects who
finished the study and those who abandoned early had
depressions of longer duration than subjects who left
treatment later.
95
The type of work and how an individual handles his or
her working activity have been important issues in
depression research. The GAZEL study evaluated a
cohort of 10 519 employees of the French national elec-
tricity and gas company over 3 years.This study showed
that demanding work and poor social support were good
predictors for the appearance of depressive symptoms
regardless of the subject’s personality.
96
Among the steps and programs developed to improve
adherence to antidepressive treatment,one of the most
important is the role of pharmacists as “cotherapists”to
reinforce the patient’s attitude towards medication.
97,98
Advice over the telephone and monitoring of medica-
tion, especially at the outset of treatment in primary
care, have also proven useful,
99-101 as have informational
mailings,either exclusively
102 or in combination with tele-
phone advice.
103An interactive voice response system for
improving compliance with antidepressant treatment is
currently being developed with promising results.
104
Depressed patients who are treated by psychiatrists have
better adherence rates and take the new antidepressants
for longer periods and at more appropriate dosages than
those receiving treatment from primary care physi-
cians.
105 Since more depression patients are treated in the
primary care system and many have persistent symp-
toms, psychoeducation programs have been designed
and the frequency of visits from psychiatrists on the pri-
mary care staff have increased.This has resulted in more
adherence to therapeutic doses and fewer depressive
symptoms than among patients receiving conventional
treatment.
106 Furthermore, patients who are allowed to
set their own schedule for taking antidepressants are
more likely to comply with the program,although after
12 weeks adherence drops in any kind of medication
administration program.
107
Bipolar disorder
Bipolar disorder is a chronic illness requiring lifelong
prophylactic treatment to reduce relapse and recurrence,
and ideally to keep symptoms in remission.Most studies
on adherence to bipolar pharmacological treatment
have been carried out with outpatients taking lithium;
noncompliance figures range from 18% to 52%.
108-110 In
a 6-year naturalistic study, Schumann et al found that
overall medication discontinuance rates were 54%;it is
noteworthy that 43% of those who went off the medica-
tion did so within the first 6 months of treatment.
111 In a
group of 101 patients hospitalized for acute mania,64%
had been noncompliant with treatment the month prior
to hospitalization.
112A prospective evaluation at 1 year
of patients hospitalized for acute mania or a mixed
episode revealed a 51% noncompliance rate with mood
stabilizers.
113 Levantes et al found an overall adherence
rate of 74% in lithium treatment after 6 months of obser-
vation;slow-release lithium carbonate (400 mg) was bet-
ter tolerated and allowed for better adherence than stan-
dard tablets (250 mg).
114
Schou,a renowned figure in lithium use in psychiatry,has
insisted that noncompliance is the most frequent cause
for recurrence during prophylactic treatment.He has also
indicated that this treatment must be used in conjunction
with procedures that reinforce compliance through infor-
mation,support,and supervision.
115 Instruments such as
the Lithium Attitudes Questionnaire,developed to eval-
uate patients’ attitudes towards lithium,have shown that
negative attitudes are associated with higher noncompli-
ance rates.
111
In ascertaining why patients discontinued their lithium
treatment,Pope and Scott found that the most commonly
endorsed items were “bothered by the idea of a chronic
illness,” “bothered by the idea that moods were con-
trolled by medication,”and “felt depressed.”In contrast,
clinicians believed that patients stopped taking lithium
either because of “feeling down”or because of “feeling
better,” assuming that if they felt well they no longer
needed medication.
116
Rather than greater knowledge about lithium, what is
needed is to modify patients’ attitudes to improve adher-
ence.
117 Being female,older,living with a partner,having
a higher educational level, and perceiving the benefits
and obstacles of lithium treatment were all factors in bet-
ter compliance.
118,119 Studies show that bipolar patients
with substance use disorder have better compliance whenClinical research
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taking valproate than lithium,and that poor adherence
to lithium is the result of side effects.
120 One of the main
side effects of mood stabilizers is weight gain,which can
be a major obstacle to maintaining prophylactic treat-
ment.Topiramate is an alternative to lithium and val-
proate that causes a drop in weight and body mass
index.
121Weight monitoring and education on this issue
must not be overlooked in order to promote better
adherence.
Conclusion
Today’s maintenance treatments of various mental ill-
nesses are very challenging to the clinician because his or
her responsibility in a patient’s adherence to treatment
goes beyond simply a correct diagnosis and choice of
medication.A good doctor-patient relationship with an
emphasis on communication is the best way to ensure
compliance with therapy.Given the high noncompliance
rates,this is an issue that must be dealt with in each clini-
cal appointment. Family participation, patient psycho-
education,and reinforcement programs with telephone
calls and information mailings all help improve adher-
ence.The concept of therapeutic dosage should be para-
mount from the onset,ie,the smallest effective dosage,
taken the fewest times per day, with the fewest side
effects,and for the length of time needed to obtain remis-
sion of symptoms and the best quality of life. Despite
physicians’ best efforts,patient’s decision is the main rea-
son for abandoning treatment.
122Attitudes and behaviors
toward the illness and treatment are better adherence
predictors than are drugs’ side effects.Clinical guidelines
are a major help in improving treatments,but clinicians
do not always follow these guidelines.
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Respuesta insuficiente al tratamiento: 
más allá de los medicamentos
En psiquiatría uno de los factores que afecta la
mala respuesta a los tratamientos farmacológicos
es la adherencia. El incumplimiento en los trata-
mientos de mantención de enfermedades crónicas
como la esquizofrenia y los trastornos afectivos
puede superar el 50%. En la mala adherencia hay
factores dependientes del fármaco (tolerancia, com-
plejidad de la indicación, efectos indeseables,
costo), del paciente (síntomas de la enfermedad,
comorbilidad, capacidad de insight, sistema de cre-
encias y ambiente sociocultural) y del médico (estilo
de comunicación y psicoeducación). Los tratamien-
tos psicosociales deben estar incorporados junto
con los fármacos en la fase de mantención para
ayudar a una mejor adherencia al tratamiento bio-
lógico y conseguir, a través del manejo de variables
psicológicas, un mejor funcionamiento social, labo-
ral y familiar. En este artículo se revisan los concep-
tos de adherencia e incumplimiento, y su impacto
en los tratamientos de mantención, como también
el efecto que tiene el manejo de los factores psico-
sociales en el tratamiento psiquiátrico.
Réponse insuffisante au traitement : 
au-delà du médicament
En psychiatrie, l’un des principaux facteurs contri-
buant à la réponse insuffisante au traitement phar-
macologique est le manque d’adhésion du patient.
La non-observance du traitement d’entretien pour
les maladies chroniques comme la schizophrénie et
les troubles affectifs peut dépasser 50 %. La mau-
vaise adhésion thérapeutique peut être due à des
facteurs liés au médicament (tolérance, complexité
de la prescription, effets secondaires, ou coût), à des
variables liées au patient (symptômes de la maladie,
comorbidité, intuition, convictions, ou environne-
ment socioculturel), et à des facteurs liés au médecin
(communication ou mode psychoéducatif). Les trai-
tements psychosociaux doivent être utilisés conjoin-
tement avec les médicaments pendant la période
d’entretien pour améliorer l’adhésion au traitement
et pour obtenir – grâce à la gestion des variables psy-
chosociales – un meilleur fonctionnement social, pro-
fessionnel et familial. Cet article décrit les concepts
d’adhésion et de non-observance et leur impact sur
la poursuite des traitements, ainsi que l’effet de la
gestion des facteurs psychosociaux dans les traite-
ments psychiatriques.
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